SciClone granted exclusive license to co-develop and commercialize RRx-001 upon approval in the Greater China RegionUnder the terms of the agreement, SciClone will obtain exclusive licensing rights to co-develop and commercialize RRx-001, for the treatment of cancer in humans, within "SciClone is a dynamic, innovative and forward-thinking company with whom we have excellent personal chemistry and are fully aligned as we seek to improve cancer outcomes in the US, "This agreement marks our next phase of growth, expanding development of our Phase 3 study as a global trial and strengthening the company financially to support a number of exciting programs," added EpicentRx's CFO, Franck Brinkhaus. At the moment, then, there are (at least) four investigations by Chinese authorities into foreign companies: Baxter, Sanofi, GSK and AstraZeneca. This small molecule drug acts to normalize the tumor microenvironment, activate the tumor associated macrophages (TAMs) of the innate immune system, and sensitize solid tumors to standard therapies," said RRx-001 is a well-tolerated next generation small molecule immunotherapeutic that targets the CD47 – SIRPα axis and repolarizes tumor associated macrophages (TAMs) and other immunosuppressive cells in the tumor microenvironment to an immunostimulatory phenotype as well as improves tumor blood flow to enhance oxygen supply and drug delivery. Cyclone Pharmaceuticals Pvt Ltd is group company of Cyclone India Group. These risks may cause actual results to differ materially from those expressed or implied by forward-looking statements in this press release. SciClone Pharmaceuticals International Ltd Baxter Discloses Possible Bribery in China 02 August 2013 At the moment, then, there are (at least) four investigations by Chinese authorities into foreign companies: Baxter, Sanofi, GSK and AstraZeneca. Some executives who already know the perils of the Foreign Corrupt Practices Act are learning that they may have even more to fear from angry investors. Clinical studies for the drug have also been conducted for the treatment of colorectal cancer, brain metastases and glioblastoma and are planned in leukemia and myelodysplastic syndrome.EpicentRx is an immuno-oncology company whose focus is to identify and develop less toxic and more effective immunotherapy-based anti-cancer treatments that are active not only as single agents, but that also sensitize tumors to the cytotoxic effects of chemotherapy, radiation and immune checkpoint blockade.
Simone Nadelhofer "RRx-001 was initially identified and sourced from the aerospace industry and has been developed by EpicentRx as a novel first-in-class therapy. The company is also advancing multiple programs through its smart virus AdAPT platform, including three anti-SARS-CoV-2 vaccines, a TGF-beta "trap" starting Phase 1, and various personalized cancer vaccines that have shown to be effective in both chemotherapy and immune resistant tumors. EpicentRx's lead program is among a portfolio of novel dinitroazetidine-based drugs that downregulate CD47 – SIRPα to alter the tumor microenvironment and optimize immune responses as well as normalize the tumor vasculature for better drug and oxygen delivery, and has been tested in several clinical trials including an ongoing Phase 3 study in SCLC. In a November speech, Lanny Breuer, head of the Justice Department’s Criminal Division, put the pharmaceutical industry on notice that it would be subject to increased Foreign Corrupt Practices Act enforcement. SciClone maintains a pipeline of products that it is shepherding through the approval process in China; therapeutic areas of focus include oncology, infectious disease, and cardiovascular disorders.
The Justice Department's industry-wide probe of pharmaceutical companies demonstrates the dangers in inadequate third-party due diligence. RRx-001 is currently a Phase 3 trial called REPLATINUM trial for the treatment of third-line and beyond SCLC. Anand Doobay About SciClone Pharmaceuticals International Ltd. SciClone Pharmaceuticals is a privately-owned specialty pharmaceutical company with a … In some cases, you can identify forward-looking statements by terminology such as "may," "might," "will," "should," "expect," "plan," "anticipate," "project," "believe," "estimate," "predict," "potential," "intend" or "continue," the negative of terms like these or other comparable terminology, and other words or terms of similar meaning. These include statements about the clinical activity of RRx-001, any additional equity investment by SciClone, or the receipt of future milestones and royalties from SciClone.
Established in 2005 as a small Pharmaceutical consultancy company by a Pharma technocrat Mr.Sachin Bhalekar. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Although EpicentRx believes that it has a reasonable basis for forward-looking statements contained herein, they are based on current expectations about future events affecting EpicentRx and are subject to risks, uncertainties and factors relating to its operations and business environment, all of which are difficult to predict and many of which are beyond its control.